AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Identification of C3 complement molecule at the site of injury to blood vessels in the retina of oxygen exposed newborn mice
Summary
John T. Flynn, M.D.
Technology Benefits
This is an alternative treatment for ROP. Current treatments are invasive surgeries on the eye, with no information on the long-term effects. Patent information:Patent Pending (WO/2012/118833)
Technology Application
Method for treating, preventing, or reducing oxygen damage in ROPNew Information regarding the underlying cause of ROP will lead to:Better treatment protocols at Neonatal Intensive Care Units (NICUs) to prevent ROPIdentification of additional risk factor(s)Development of drug therapy
Detailed Technology Description
John T. Flynn, M.D.
Country/Region
USA
For more information, please click Here
